Randox Laboratories Ltd. | Date: 2017-01-04
Components for enabling immunodection of methoxetamine are described including immunogens, haptens, antibodies and kits.
Randox Laboratories Ltd. | Date: 2015-06-15
A liquid sample collection device is provided. The liquid sample collection device comprises a housing including a liquid collection chamber, and a liquid supply conduit extending from an inlet port and in use generally downwardly to the collection chamber, wherein the collection chamber includes an air vent port located such that in use liquid supplied to the collection chamber through the liquid supply conduit displaces air through the air vent port, and wherein the liquid supply conduit follows a meandering path including at least one air trap section defined at the junction between portions of the conduit extending with upward and downward components respectively, whereby in use once the air vent port is closed, air is displaced along the liquid supply conduit until it is trapped by the air trap section thereby preventing further liquid flow through the conduit.
Randox Laboratories Ltd. | Date: 2016-11-23
A biochip well is disclosed, including a vessel containing a well therewithin, the vessel forming at least base and side walls of the well and defining at least one aperture giving access to the well, and further including retaining means for holding a biochip at a predetermined position within the well, the well including a laterally offset region into which the biochip does not protrude when held at the predetermined position by the retaining means. Also disclosed are sealed well assemblies and apparatus and methods for opening sealed wells.
Randox Laboratories Ltd. | Date: 2017-02-08
The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-29-2016 | Award Amount: 15.57M | Year: 2017
PIXAPP will establish the worlds first open access Photonic Integrated Circuit (PIC) assembly & packaging Pilot Line. It combines a highly-interdisciplinary team of Europes leading industrial & research organisations. PIXAPP provides Europes SMEs with a unique one-stop-shop, enabling them to exploit the breakthrough advantages of PIC technologies. PIXAPP bridges the valley of death, providing SMEs with an easy access route to take R&D results from lab to market, giving them a competitive advantage over global competition. Target markets include communications, healthcare & security, which are of great socio-economic importance to Europe. PIXAPPs manufacturing capabilities can support over 120 users per year, across all stages of manufacturing, from prototyping to medium scale manufacture. PIXAPP bridges missing gaps in the value chain, from assembly & packaging, through to equipment optimisation, test and application demonstration. To achieve these ambitious objectives, PIXAPP will; 1) Combine a group of Europes leading industrial & research organisations in an advanced PIC assembly & packaging Pilot Line facility.2) Develop an innovative Pilot Line operational model that coordinates activities between consortium partners & supports easy user access through a single entry point. 3) Establish packaging standards that provide cost-efficient assembly & packaging solutions, enabling transfer to full-scale industrial manufacture. 4) Create the highly-skilled workforce required to manage & operate these industrial manufacturing facilities.5) Develop a business plan to ensure Pilot Line sustainability & a route to industrial manufacturing. PIXAPP will deliver significant impacts to a wide stakeholder group, highlighting how industrial & research sectors can collaborate to address emerging socio-economic challenges.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 2.12M | Year: 2016
MAST4HEALTH is set on the concept of a multidisciplinary approach to assess a non-pharmacological intervention for managing NAFLD/NASH, one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients. Because of limitations in current NAFLD treatment therapies, many new efforts focus on exploring non-pharmacologic means for managing the disease and in particular through dietary substances or bioactive phytochemicals in fruits, vegetables, and plants or their products. MAST4HEALTH aims at exploring the effect of Mastiha, a natural product of Greece which was recently shown to possess antioxidant/anti-inflammatory and lipid lowering properties. We designed a multicenter randomized double blind placebo controlled (parallel arm) clinical trial to test the effectiveness of Mastiha supplement as new non-pharmacologic strategy for NAFLD/NASH treatment. MAST4HEALTH will explore gene-diet interactions, more specifically the potential personalized activity of the Mastiha, and correlate genetic and epigenetic markers with metabolomic and intestinal microbiota profiles pre- and post-intervention. The effectiveness of the proposed intervention will be evaluated via clinical and laboratory markers of the disease. To this end, MAST4HEALTH will train a number of researchers and PhD students in multidisciplinary approaches of this survey. MAST4HEALTH is expected to build and enhance cooperation among partners meanwhile strengthening the interaction between our academic and non-academic sectors
Randox Laboratories Ltd | Date: 2016-07-01
Components for enabling immunodetection of methoxetamine are described including immunogens, haptens, antibodies and kits.
Randox Laboratories Ltd. | Date: 2016-08-17
Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[(1-(dimethylamino)cylohexyl)methyl]benzamide and 3,4,-dichloro-N-[(1-(methylamino)cylohexyl)methyl]benzamide, as well as the precursory immunogens, are described.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 150.00K | Year: 2016
Abstract: In 2012, 5242 people in the UK lost their life to bladder cancer. The most common symptom of bladder cancer is blood in the urine (haematuria), which is usually painless. Haematuria can be frank (macroscopic), visible to the patient, or invisible (microscopic), which is normally detected during a routine urine dipstick test. Haematuria in its visible and invisible forms can represent a disease process within the urinary tract. Patients presenting with haematuria require investigations, including cystoscopy (endoscopy of the urinary baldder), cytology (which examines the appearance of cells in voided urine), and imaging of their urinary tracts, to identify the source of bleeding. Cystoscopy (the gold standard for bladder cancer detection) allows direct observation of the bladder, but is invasive and uncomfortable for the patient. If a suspicious region is observed a biopsy is needed. Cystoscopy does not allow for upper track visualisation, does not always detect small areas of carcinoma in situ, can give false positive results, is embarrassing for the patient and can be biased by the risk category of the patient. Cytology, has high specificity but poor sensitivity, and hence, cannot act alone for the diagnosis of urothelial cancer. Less than 20% of patients with macroscopic, and <5% with microscopic haematuria have bladder cancer. As such, it has been estimated that in the UK the total cost of managing patients with haematuria who are found not to have bladder cancer is >£33.5 million. Consequently, haematuria is a significant healthcare burden, which is only set to increase because of the aging population. Therefore, there is a strong clinical need for tests which can at least stratify haematuria patients and if possible, be diagnostic. Randox in collaboration with Queens University Belfast (QUB) and The Belfast Trust have identified a diagnostic classifier for risk stratification of haematuria patients (DCRSHP). The DCRSHP is a urine-based diagnostic test that is non-invasive, rapid, easy to use and interpret results, has high sensitivity and specificity, is unbiased, and allows high-throughput screening for hundreds of haematuria patient samples. Use of the DCRSHP at the GP surgery or the haematuria clinic will significantly reduce the number of low-risk patients that are currently red flagged for cystoscopy and improve waiting times for haematuria patients who do require diagnostic services i.e. those patients deemed at high risk. The SBRI grant funding will allow us to engage with Health Economists/Diagnostic Evidence Cooperative to establish the validity and value of our test in a clinical setting.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 149.93K | Year: 2016
For the 2,900 patients per year in the UK diagnosed with Acute Myeloid Leukemia (AML), aggressive cytarabine based chemotherapy is given at diagnosis, yet, up to 40% of patients do not respond to this treatment. The majority of AML patients are >60 years old and, with the rise in the elderly population, increased prevalence of the disease is predicted. Currently, patients in this age range who are deemed fit for treatment are prescribed cytarabine, where outcome to the drug regimen is uninformed and is based on a trial-and-error approach. A rapid and highly accurate stratification-based approach would enable patients with drug responsive cancer to be treated with lower drug doses, reducing acute and long-term side-effects, including the need for antimicrobials and blood product support and future risk of secondary cancers. In order to add economic value and provide a stratified based treatment regimen, clinicians need assistance in selecting the best treatment and care for patients as early as possible. We provide a solution to this clinical problem by offering a rapid, in vitro assay, using a bioluminescent bacterial biosensor, determining patient response to cytarabine with a AUROC value of 0.8. The technology is reliable, robust and enables stratification to identify patients who will benefit from chemotherapeutic treatment, particularly at diagnosis. The aim of this project is to enable engagement with a Diagnostic Evidence Cooperative to provide an economic analysis of this test providing evidence to demonstrate its value for inclusion in routine practice and to work toward best methods of introducing the test into the clinical pathway.